Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Lurasidone Hydrochloride

These are related to the Lurasidone Hydrochloride news, in which you can learn about the latest trends in Lurasidone Hydrochloride and related information industry, to help you better understand and expand Lurasidone Hydrochloride market.
  • Drug Patent & Exclusivity Expiration Report - Week of June 23 2025

    Drug Patent & Exclusivity Expiration Report - Week of June 23 2025

    2025-06-23

    This week, there are 18 drugs in the patent and exclusivity list. They are: - SUNOVION PHARMACEUTICALS INC's LATUDA, containing active ingredient LURASIDONE HYDROCHLORIDE - VERTEX PHARMACEUTICALS INC's TRIKAFTA (COPACKAGED), containing active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - VERTEX PHARMACEUTICALS INC's KALYDECO, containing active ingredient IVACAFTOR - VERTEX PHARMACEUTICALS INC's SYMDEKO (COPACKAGED), containing active ingredient IVACAFTOR; IVACAFTOR, TEZACAFTOR - TAKEDA PHARMACEUTICALS USA INC's KAZANO, containing active ingredient ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - VERTEX PHARMACEUTICALS INC's ALYFTREK, containing active ingredient DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM Read More